Histone deacetylase 5 regulates the inflammatory response of macrophages

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 9, 2015, Pages 2162-2171

  Poralla, Lukas ^a   Stroh, Thorsten ^a   Erben, Ulrike ^a   Sittig, Marie ^a   Liebig, Sven ^a   Siegmund, Britta ^a   Glauben, Rainer ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytokine; Histone deacetylase; Inflammation; Macrophage; Tumour necrosis factor

Indexed keywords

GAMMA INTERFERON; HISTONE DEACETYLASE 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; HDAC5 PROTEIN, HUMAN; HDAC5 PROTEIN, MOUSE; HISTONE DEACETYLASE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CHROMATIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFLAMMATION; LUCIFERASE ASSAY; MACROPHAGE ACTIVATION; MACROPHAGE INFLAMMATION; MURINE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SEQUENCE ANALYSIS; STIMULUS RESPONSE; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; KINETICS; MACROPHAGE; METABOLISM; MOUSE; PATHOLOGY; RAW 264.7 CELL LINE; U-937 CELL LINE;

ANIMALS; CYTOKINES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASES; HUMANS; INFLAMMATION; KINETICS; MACROPHAGES; MICE; NF-KAPPA B; RAW 264.7 CELLS; RNA, MESSENGER; RNA, SMALL INTERFERING; U937 CELLS;

EID: 84940792645     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12595     Document Type: Article

References (44)

1. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009; 10: 32-42.
2. Spange S, Wagner T, Heinzel T, et al. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2009; 41: 185-98.
3. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol. 2006; 209: 611-6.
4. McKinsey TA, Zhang CL, Olson EN. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA. 2000; 97: 14400-5.
5. Grozinger CM, Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA. 2000; 97: 7835-40.
6. Grant C, Rahman F, Piekarz R, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010; 10: 997-1008.
7. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007; 25: 84-90.
8. Vojinovic J, Damjanov N, D'Urzo C, et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011; 63: 1452-8.
9. Nishida K, Komiyama T, Miyazawa S, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 2004; 50: 3365-76.
10. Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005; 11: 1-15.
11. Glauben R, Batra A, Fedke I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol. 2006; 176: 5015-22.
12. Glauben R, Batra A, Stroh T, et al. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 2008; 57: 613-22.
13. Glauben R, Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol Med. 2011; 17: 426-33.
14. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006; 177: 7303-11.
15. Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. J Innate Immun. 2011; 3: 550-64.
16. Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med. 2009; 206: 1883-97.
17. Lewis EC, Blaabjerg L, Storling J, et al. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet beta cells in vivo and in vitro. Mol Med. 2011; 17: 369-77.
18. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA. 2002; 99: 2995-3000.
19. Schmeck B, Lorenz J, N'Guessan PD, et al. Histone acetylation and flagellin are essential for Legionella pneumophila-induced cytokine expression. J Immunol. 2008; 181: 940-7.
20. Alenghat T, Osborne LC, Saenz SA, et al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature. 2013; 504: 153-7.
21. Chen X, Barozzi I, Termanini A, et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci USA. 2012; 109: E2865-74.
22. Stroh T, Erben U, Kuhl AA, et al. Combined pulse electroporation-a novel strategy for highly efficient transfection of human and mouse cells. PLoS ONE. 2010; 5: e9488.
23. Downes M, Ordentlich P, Kao HY, et al. Identification of a nuclear domain with deacetylase activity. Proc Natl Acad Sci USA. 2000; 97: 10330-5.
24. Sugimoto M, Esaki N, Tanaka H, et al. A simple and efficient method for the oligonucleotide-directed mutagenesis using plasmid DNA template and phosphorothioate-modified nucleotide. Anal Biochem. 1989; 179: 309-11.
25. Baek YS, Haas S, Hackstein H, et al. Identification of novel transcriptional regulators involved in macrophage differentiation and activation in U937 cells. BMC Immunol. 2009; 10: 18.
26. Ku CS, Pham TX, Park Y, et al. Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-kappaB pathway in macrophages and splenocytes. Biochim Biophys Acta. 2013; 1830: 2981-8.
27. Aung HT, Schroder K, Himes SR, et al. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J. 2006; 20: 1315-27.
28. Jiang M, Xiang Y, Wang D, et al. Dysregulated expression of miR-146a contributes to age-related dysfunction of macrophages. Aging Cell. 2012; 11: 29-40.
29. Schroder K, Sweet MJ, Hume DA. Signal integration between IFNgamma and TLR signalling pathways in macrophages. Immunobiology. 2006; 211: 511-24.
30. Jurkovich GJ, Mileski WJ, Maier RV, et al. Interferon gamma increases sensitivity to endotoxin. J Surg Res. 1991; 51: 197-203.
31. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol. 1996; 157: 2116-22.
32. Cramer LA, Nelson SL, Klemsz MJ. Synergistic induction of the Tap-1 gene by IFN-gamma and lipopolysaccharide in macrophages is regulated by STAT1. J Immunol. 2000; 165: 3190-7.
33. Dalpke AH, Eckerle S, Frey M, et al. Triggering of Toll-like receptors modulates IFN-gamma signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling. Eur J Immunol. 2003; 33: 1776-87.
34. Klampfer L, Huang J, Swaby LA, et al. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem. 2004; 279: 30358-68.
35. Kramer OH, Baus D, Knauer SK, et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 2006; 20: 473-85.
36. Lee CW, Lin CC, Luo SF, et al. Tumor necrosis factor-alpha enhances neutrophil adhesiveness: induction of vascular cell adhesion molecule-1 via activation of Akt and CaM kinase II and modifications of histone acetyltransferase and histone deacetylase 4 in human tracheal smooth muscle cells. Mol Pharmacol. 2008; 73: 1454-64.
37. Vashisht Gopal YN, Arora TS, Van Dyke MW. Tumour necrosis factor-alpha depletes histone deacetylase 1 protein through IKK2. EMBO Rep. 2006; 7: 291-6.
38. Yu Z, Zhang W, Kone BC. Histone deacetylases augment cytokine induction of the iNOS gene. J Am Soc Nephrol. 2002; 13: 2009-17.
39. Miao F, Gonzalo IG, Lanting L, et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem. 2004; 279: 18091-7.
40. Urbich C, Rossig L, Kaluza D, et al. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood. 2009; 113: 5669-79.
41. Gannon AM, Frizzell A, Healy E, et al. MutSbeta and histone deacetylase complexes promote expansions of trinucleotide repeats in human cells. Nucleic Acids Res. 2012; 40: 10324-33.
42. Weems J, Olson AL. Class II histone deacetylases limit GLUT4 gene expression during adipocyte differentiation. J Biol Chem. 2011; 286: 460-8.
43. Usami M, Kishimoto K, Ohata A, et al. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res. 2008; 28: 321-8.
44. Furumai R, Ito A, Ogawa K, et al. Histone deacetylase inhibitors block nuclear factor-kappaB-dependent transcription by interfering with RNA polymerase II recruitment. Cancer Sci. 2011; 102: 1081-7.